Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
Submitted by
admin
on November 4, 2016 - 9:18am
Source:
Yahoo
News Tags:
FDA
Genentech
Halozyme
rituximab
blood cancer
Headline:
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
Do Not Allow Advertisers to Use My Personal information
